Chinese maker of biomedical refrigeration equipment — ultra-low-temperature freezers and vaccine cold-chain systems — part of the Haier Group.
Chinese maker of biomedical refrigeration equipment — ultra-low-temperature freezers and vaccine cold-chain systems — part of the Haier Group.
Sells equipment into government-funded programs such as vaccine cold chains, and to labs and hospitals, so demand arrives in procurement waves; it surged during the pandemic vaccine rollouts. Haier Group, the home-appliance maker, is the controlling shareholder.
Moat: narrow (brand, scale, distribution). Haier Group brand and global distribution scale versus specialized biomedical refrigeration competitors.
Headquarters: Qingdao, China · Founded: 1996 · Employees: 2,945
Size Qingdao Haier Biomedical (688139.SS) is a China Industrials company (Industrial Machinery) with a market value of $1.45B, the 1560th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥30.36 on 18 Nov 2026.
Performance Over six months the shares fell 10.6%, against -26.6% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 12.2% over the last twelve months (peer median +11.8%); the operating margin is 8.6% (peer median 12.9%).
Valuation It trades at 33.4× forward earnings against a peer median of 22.7× (7th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.4 points below its cost of capital (9.0% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.53B | CN¥2.32B | CN¥2.27B | CN¥2.27B | CN¥2.84B |
| Revenue growth | — | +2% | 0% | -20% | — |
| Gross profit | CN¥1.24B | CN¥1.00B | CN¥1.01B | CN¥1.08B | CN¥1.32B |
| EBITDA | n/a | CN¥302M | CN¥404M | CN¥395M | CN¥608M |
| Net income | CN¥272M | CN¥251M | CN¥367M | CN¥406M | CN¥601M |
| Free cash flow | CN¥309M | CN¥171M | CN¥181M | CN¥114M | CN¥404M |
| Capital expenditure | CN¥90.3M | CN¥119M | CN¥127M | CN¥177M | CN¥294M |
| Total debt | CN¥206M | CN¥124M | CN¥113M | CN¥123M | CN¥175M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Qingdao Haier Biomedical 688139.SS | $1.45B | -11% | +12% | 9% | 33.4× | 18.8% |
| Thermo Fisher Scientific TMO | $257B | +53% | +8% | 19% | 25.7× | 21.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688139.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.4% | -10.6% | 7th highest of 21 |
| 6-month return | -10.6% | -26.6% | 6th highest of 21 |
| Distance from 52-week high | -21.8% | -45.8% | 2nd highest of 21 |
| Revenue growth (TTM) | +12.2% | +11.8% | 10th highest of 21 |
| Operating margin | 8.6% | 12.9% | 8th lowest of 21 |
| Forward P/E | 33.4× | 22.7× | 7th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 18.8% | 9.8% | 5th most demanding of 14 |
| Growth delivered (Del g) | +10.8% | +9.8% | 6th highest of 14 |
| Hurdle (Req g minus delivered) | +8.1 pp | +1.8 pp | 5th most demanding of 14 |
| ROIC minus cost of capital | -2.4 pp | +1.3 pp | 7th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Qingdao Haier Biomedical 688139.SS | China | $1.45B | -11% | +12% | 9% | 33.4× | 18.8% | +10.8% |
| Jiangxi Guoke Defence 688543.SS | China | $1.45B | -19% | +2% | 16% | 44.1× | n/a | n/a |
| Ningbo PIA Automation 688306.SS | China | $1.45B | -23% | +7% | 4% | 159.0× | 31.7% | +8.7% |
| Interroll INRN.SW | Switzerland | $1.44B | -8% | +2% | 13% | 20.2× | 2.0% | -0.6% |
| Test Research 3030.TW | Taiwan | $1.46B | -45% | +32% | 37% | n/a | -1.5% | +11.3% |
| Ningbo Donly 002164.SZ | China | $1.46B | +31% | +5% | 5% | n/a | n/a | n/a |
| Helios Technologies HLIO | United States | $1.47B | -43% | +12% | 13% | 13.8× | 9.8% | +9.9% |
| Zhuzhou Huarui Precision Cutting Tools 688059.SS | China | $1.47B | -32% | +23% | 36% | 18.5× | n/a | n/a |
| Precision Tsugami (China) 1651.HK | Hong Kong | $1.47B | -42% | +25% | 30% | 7.0× | -17.7% | +9.8% |
| Crompton Greaves Consumer Electricals CROMPTON.NS | India | $1.43B | -29% | +12% | 8% | 22.7× | 20.0% | +11.0% |
| Tongyu Heavy Industry 300185.SZ | China | $1.43B | -24% | +6% | 4% | 39.3× | 5.0% | +3.1% |
| Goodwin GDWN.L | United Kingdom | $1.41B | +3% | +2% | 13% | n/a | 47.6% | -12.1% |
| Beijing Worldia Diamond Tools 688028.SS | China | $1.40B | -48% | +22% | 16% | 60.2× | n/a | n/a |
| Tofflon Science and Technology 300171.SZ | China | $1.40B | -3% | -2% | 6% | 33.5× | 4.7% | +14.0% |
| Ningbo Haitian Precision Machinery 601882.SS | China | $1.50B | -21% | +19% | 11% | 19.4× | 12.2% | +15.6% |
| Quick Intelligent Equipment 603203.SS | China | $1.51B | -40% | +20% | 21% | 37.9× | 28.0% | +15.2% |
| LU-VE LUVE.MI | Italy | $1.51B | -6% | +12% | 11% | 24.3× | 13.9% | +8.6% |
| Shaanxi Aerospace Power Hi-Tech 600343.SS | China | $1.38B | -58% | -15% | -24% | n/a | n/a | n/a |
| Harbin Boshi Automation 002698.SZ | China | $1.53B | -31% | -2% | 18% | 17.8× | 3.9% | +9.1% |
| Guangdong Huicheng Vacuum Technology 301392.SZ | China | $1.53B | -32% | +48% | 7% | n/a | n/a | n/a |
| Ta Liang Technology 3167.TW | Taiwan | $1.54B | -15% | +122% | 28% | 10.6× | n/a | n/a |